Key Developments: Kips Bay Medical Inc (KIPS.PK)

KIPS.PK on OTC Markets Group

0.22USD
24 Oct 2014
Price Change (% chg)

$0.03 (+15.26%)
Prev Close
$0.19
Open
$0.19
Day's High
$0.22
Day's Low
$0.19
Volume
28,624
Avg. Vol
96,817
52-wk High
$0.99
52-wk Low
$0.14

Search Stocks

Latest Key Developments (Source: Significant Developments)

Kips Bay Medical Inc receives updated CE Mark Approval
Monday, 25 Aug 2014 09:00am EDT 

Kips Bay Medical Inc:Announced that it has received an updated CE Mark approving use of new surgical implant technique for its eSVS Mesh.  Full Article

Kips Bay Medical Inc announces FDA approval for U.S. expansion of eMESH I clinical feasibility study
Monday, 17 Mar 2014 07:00am EDT 

Kips Bay Medical Inc:United States Food & Drug Administration (FDA) has granted approval for Kips Bay Medical to include more U.S. patients and U.S. study sites in 'eMESH I' clinical feasibility trial of eSVMesh.Initial approval, FDA indicated that it would allow staged enrollment within United States, starting with 15 patients at up to four sites in the United States.FDA has increased approved number of U.S. patients from 15 to 27 (15 additional from 12 enrolled to date) and increased allowed number of U.S. sites from four to 10.FDA has also approved combination of changes in application of eSVS Mesh to saphenous vein graft and to surgical implant technique for eSVS Mesh treated graft.Changes are intended to reduce the risk of early graft occlusion, make it easier to implant the eSVS Mesh and reduce procedural costs.  Full Article

Kips Bay Medical Inc announces closing of public offering of common stock, including exercise of underwriters' over-allotment option
Wednesday, 29 Jan 2014 11:45am EST 

Kips Bay Medical Inc:Says closing of its underwritten public offering of 5,250,000 shares of common stock and the sale of an additional 785,000 shares of common stock pursuant to the exercise in full by the underwriters of the over-allotment option granted to the underwriters in connection with the offering.Says the gross proceeds to Kips Bay from the offering, including the exercise of the over-allotment option by the underwriters, are $4,224,500.Says it intends to use the net proceeds of this offering for working capital and general corporate purposes.Says Aegis Capital Corp. acted as the sole book-running manager for the offering.  Full Article

Kips Bay Medical Inc announces pricing of public offering of 5,250,000 shares of common stock
Thursday, 23 Jan 2014 08:48pm EST 

Kips Bay Medical Inc:Says the pricing of its previously announced underwritten public offering.Says it is offering 5,250,000 shares of common stock at a public offering price of $0.70 per share for gross proceeds of $3,675,000, prior to deducting the underwriting discount and estimated offering expenses.Says it intends to use the net proceeds of this offering for working capital and general corporate purposes, including funding the process of seeking regulatory approval to market its eSVS Mesh in the United States and abroad, including continuing its human clinical trials.Says it has granted the underwriters a 45-day option to purchase up to an aggregate of 785,000 additional shares of common stock to cover over-allotments, if any.Says the offering is expected to close on or about January 29, 2014.Says Aegis Capital Corp. is acting as the sole book-running manager for the offering.  Full Article

Kips Bay Medical Inc announces proposed public offering of common stock
Thursday, 23 Jan 2014 04:16pm EST 

Kips Bay Medical Inc:Says its intention, subject to market and other conditions, to commence a public offering of its common stock.Says it intends to use the net proceeds of this offering for working capital and general corporate purposes, including funding the process of seeking regulatory approval to market its eSVS Mesh in the United States and abroad, including continuing its human clinical trials.Aegis Capital Corp. is acting as the sole book-running manager for the offering.  Full Article

Kips Bay Medical Inc Announces FDA Approval For Additional US Study Patients-DJ
Wednesday, 23 Jan 2013 09:20am EST 

Dow Jones reported that Kips Bay Medical Inc announced that the United States Food & Drug Administration (FDA) has granted approval for additional US patients to be enrolled in Kips Bay Medical's eMESH I clinical feasibility trial of its eSVS Mesh. In its initial approval, the FDA indicated that it would allow a staged enrollment within the United States, starting with five patients at up to four sites in the United States. The FDA has now increased the approved number of patients from five to 15. The eMESH I clinical feasibility trial is a multi-center, randomized study of external saphenous vein support using Kips Bay Medical's eSVS Mesh in CABG Surgery. The objective of this study is to demonstrate the initial safety and performance of the eSVS Mesh for use as an external saphenous vein graft (SVG) support device during coronary artery bypass (CABG) surgery. The Company expects to enroll up to 120 patients at eight European and four U.S. sites and further expects to use the data from this study as the basis for a pivotal trial in the U.S.  Full Article

Kips Bay Medical Inc Announces Closing Of $6.5 Million Public Offering Of Common Stock
Friday, 28 Dec 2012 02:00pm EST 

Kips Bay Medical Inc announced that it has closed its previously announced offering of 10,000,000 shares of its common stock for total gross proceeds of $6.5 million. After the closing of the offering, Kips Bay has 26,346,079 shares of common stock outstanding. Sunrise Securities Corp. acted as the sole book-running manager. Aegis Capital Corp. acted as co-manager.  Full Article

Kips Bay Medical Inc Announces Pricing Of Public Offering Of Common Stock
Friday, 21 Dec 2012 03:55pm EST 

Kips Bay Medical Inc announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock for total estimated gross proceeds of $6.5 million. Kips Bay Medical has also granted the underwriters a 45-day option to purchase up to 1,500,000 additional shares of common stock. The offering is subject to customary closing conditions and is expected to close on December 27, 2012. Kips Bay Medical intends to use the net proceeds of this offering to seek regulatory approval to market its eSVS Mesh in the United States and abroad, including continuing its human clinical trials for the United States Food & Drug Administration, to develop and test additional applications of its eSVS Mesh, and for working capital and general corporate purposes. Sunrise Securities Corp. is acting as the sole book-running manager. Aegis Capital Corp. is acting as co-manager.  Full Article

Search Stocks